Tagged with Cancer

Sweden Key stakeholders in Swedish pharma explain why Sweden’s record on cancer care is the best in Europe and what more still needs to be done.   National investments in cancer care have improved patient outcomes and reduced waiting times Malin Parkler, Pfizer With an estimated 18 million cases globally in…

Switzerland With cancer now causing one in eight deaths globally and, in Europe, even outpacing serious cardiovascular conditions in terms of prevalence, Switzerland has long positioned itself firmly at the vanguard of countering a disease which the World Health Organization (WHO) predicts will reach an incidence rate of 22 million new…

Oncology Cancer is on the rise in Hungary and survival rates are considerably lower than the European average. The country’s innovative pharma association has taken the initiative to suggest measures that it believes would drastically improve cancer mortality rates and quality of life for oncology patients.   Recent statistics show that…

Thailand Dr Ekaphop Sirachainan, president of the Thai Society of Clinical Oncology, explains the need to increase patient access to oncology treatment in Thailand, and the crucial need for collaboration with the public sector in terms of prevention and to spread information to all healthcare professionals. Sirachainan also underlines the importance…

Europe Janssen’s EMEA market access head Martin Price outlines the regulatory changes that need to be made for patients across Europe to better access cutting-edge cancer medicines.   Recent advances in medical science are the driving force behind the research and successful development of innovative cancer treatments in Europe. By targeting…

Europe From her vantage point as associate vice president for MSD’s Central & Eastern Europe (CEE) cluster, Gabriele Grom outlines the disparity that still exists in terms of access to cancer treatments across Europe and what must be done to bridge this gap.   Despite the existence of innovative treatments, cancer…

Spain Ines Perea, general manager for Spain and Portugal at Jazz Pharmaceuticals, a global biopharmaceutical company dedicated to developing life-changing medicines for people with limited or no options in the areas of sleep and hematology/oncology, discusses her progress over the last 14 months in nurturing the local affiliate and the importance…

Korea Dr Jin Hyoung Kang, president of the Cancer Study Group comments on the scope for oncology drug development in Korea, and the issues resulting from the structure of Korea’s healthcare system. Dr Kang also offers his foresight in relation to the greater role AI and big data will play within…

Algeria Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, outlines the progress made under Algeria’s National Cancer Plan and the steps that still need to be taken to ensure all Algerian cancer patients can receive the care they need.   It is undeniable that tangible progress has…

Korea Professor Dae Ho Lee has been researching and treating Korean cancer patients for more than 20 years and advises the current government on healthcare policy. He breaks down the benefits of MoonCare to cancer patients, the challenges facing the healthcare system, and offers some potential solutions that could be adopted…

Opinion Our contributor at large, David Crean, Managing Director for Objective Capital Partners, attended J.P. Morgan’s 2019 Health Care Investor Conference, one of the biggest events in the life sciences calendar and a fantastic indicator of what is to come in healthcare for the year ahead. Here, Crean gives us the inside scoop. …

France Frédéric Collet, president Novartis France and general manager oncology explains the rationale behind Novartis’s consistent investment in France, the current shift in the company’s corporate culture and the main challenges inherent to the unprecedented wave of innovation that is revolutionizing the health industry.   In terms of research, we have invested EUR…